Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of...
- Mechanism
- Curator reviewed
CAT-213 targets eotaxin, a member of the chemokine family of proteins that acts as messenger molecules between the cells of the immune system. During an allergic response the levels of eotaxin1 are elevated. This attracts eosinophils, a type of white blood cell, into tissues where they can degranulate causing tissue damage that occurs in a variety of allergic disorders.
- Primary indication
- Investigated for use/treatment in allergic rhinitis.Curator reviewed
- Also known as
- IMMUNOGLOBULIN G4, ANTI-(HUMAN EOTAXIN 1) (HUMAN MONOCLONAL CAT-213 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CAT-213 .KAPPA.-CHAIN, DIMER
- Code names
- CAT-213 · ICO-008
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Bertilimumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account